AHL
ARCT icon

Abel Hall LLC’s Arcturus Therapeutics ARCT Stock Holding History

Abel Hall LLC’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$108K Buy
+16,142
New +$127K 0.02% 825

Other funds holding ARCT

ELI
Empire Life Investments Toronto, Ontario, Canada $1.79B AUM 38.49% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
FAM
Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
S
SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Abel Hall LLC's ARCT Position: Q2 2026 in Review

Abel Hall LLC opened a new position in Arcturus Therapeutics (ARCT) in Q2 2026: 16,142 shares worth $108K. The stake represents 0.02% of the portfolio and ranks #825 among its holdings.

20 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • Abel Hall LLC held 16,142 shares of Arcturus Therapeutics worth $108K as of Q2 2026.
  • Arcturus Therapeutics was a new Abel Hall LLC position in Q2 2026.
  • Arcturus Therapeutics made up 0.02% of Abel Hall LLC's portfolio in Q2 2026, its #825 holding.
  • 20 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.